Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | OCT 02 | CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt |
| NEWS 3 | OCT 19 | BEILSTEIN updated with new compounds |
| NEWS 4 | NOV 15 | Derwent Indian patent publication number format enhanced |
| NEWS 5 | NOV 19 | WPIX enhanced with XML display format |
| NEWS 6 | NOV 30 | ICSD reloaded with enhancements |
| NEWS 7 | DEC 04 | LINPADOCDB now available on STN |
| NEWS 8 | DEC 14 | BEILSTEIN pricing structure to change |
| NEWS 9 | DEC 17 | USPATOLD added to additional database clusters |
| NEWS 10 | DEC 17 | IMSDRUGCONF removed from database clusters and STN |
| NEWS 11 | DEC 17 | DGENE now includes more than 10 million sequences |
| NEWS 12 | DEC 17 | TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment |
| NEWS 13 | DEC 17 | MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary |
| NEWS 14 | DEC 17 | CA/CAplus enhanced with new custom IPC display formats |
| NEWS 15 | DEC 17 | STN Viewer enhanced with full-text patent content from USPATOLD |
| NEWS 16 | JAN 02 | STN pricing information for 2008 now available |
| NEWS 17 | JAN 16 | CAS patent coverage enhanced to include exemplified prophetic substances |
| NEWS 18 | JAN 28 | USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats |
| NEWS 19 | JAN 28 | MARPAT searching enhanced |
| NEWS 20 | JAN 28 | USGENE now provides USPTO sequence data within 3 days of publication |
| NEWS 21 | JAN 28 | TOXCENTER enhanced with reloaded MEDLINE segment |
| NEWS 22 | JAN 28 | MEDLINE and LMEDLINE reloaded with enhancements |
| NEWS 23 | FEB 08 | STN Express, Version 8.3, now available |
| NEWS 24 | FEB 20 | PCI now available as a replacement to DPCI |
| NEWS 25 | FEB 25 | IFIREF reloaded with enhancements |
| NEWS 26 | FEB 25 | IMSPRODUCT reloaded with enhancements |
| NEWS 27 | FEB 29 | WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification |
| NEWS 28 | MAR 31 | IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats |
| NEWS 29 | MAR 31 | CAS REGISTRY enhanced with additional experimental spectra |
| NEWS 30 | MAR 31 | CA/CAplus and CASREACT patent number format for U.S. applications updated |
| NEWS 31 | MAR 31 | LPCI now available as a replacement to LDPCI |
| NEWS 32 | MAR 31 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

```
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:58:03 ON 31 MAR 2008

=> File Medline EMBASE Biosis Caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:58:18 ON 31 MAR 2008

FILE 'EMBASE' ENTERED AT 16:58:18 ON 31 MAR 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:58:18 ON 31 MAR 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 16:58:18 ON 31 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> S (alpha 1-antitrypsin) (6a) powder
L1            6 (ALPHA 1-ANTITRYPSIN) (6A) POWDER

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l1
DUPLICATE PREFERENCE IS 'BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L1
L2             6 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)

=> d l2 1-6 bib ab

L2   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:672983  CAPLUS
DN   147:102152
TI   pharmacetical powder compositions for inhalation
IN   Mueller-Walz, Rudi
PA   Jagotec A.-G., Switz.
SO   PCT Int. Appl., 30pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2007068443 | A1 | 20070621 | WO 2006-EP11941 | 20061212 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI GB 2005-25254 A 20051212

AB A pharmacol. powder for inhalation comprising fine particles of a drug and particles of a force-controlling agent, wherein the particles of the force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The powder may further comprise particles of a carrier material for supporting the drug particles. The force-controlling agent may be selected from: amino acids, peptides and polypeptides having a mol. weight of 0.25 to 1000 KDa; phospholipids; titanium dioxide; aluminum dioxide; silicon dioxide; starch; and salts of fatty acids. Also disclosed is a method of making such a powder for inhalation comprising mixing a force-controlling agent with particles of one or more pharmacol. active materials to obtain a mixture in which the particles of the force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The mixing step may be achieved by sieving, mixing or blending, micronizing and/or co-micronizing the particles of one or more pharmacol. active materials and particles of force-controlling agents. A powder formulation consisting of glycopyrrolate, magnesium stearate and lactose monohydrate was obtained. The dry powder blend achieved is homogeneous and the blend has satisfying blend homogeneity.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:451414 CAPLUS
DN 142:487376
TI Dry recombinant human alpha 1-antitrypsin formulation
IN Nayar, Rajiv; Manning, Mark G.; Barr, Philip J.; Pemberton, Philip A.; Bathurst, Ian C.; Gibson, Helen
PA Arriva-Prometic Inc., Can.
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2005047323 | A1 | 20050526 | WO 2004-GB4740 | 20041110 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| | AU 2004288854 | A1 | 20050526 | AU 2004-288854 | 20041110 |
| | CA 2545458 | A1 | 20050526 | CA 2004-2545458 | 20041110 |
| | EP 1685160 | A1 | 20060802 | EP 2004-798463 | 20041110 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| | JP 2007534633 | T | 20071129 | JP 2006-538939 | 20041110 |
| | US 20070105768 | A1 | 20070510 | US 2006-578692 | 20060826 |
| PRAI | US 2003-518803P | P | 20031110 | | |
| | US 2003-519946P | P | 20031114 | | |
| | WO 2004-GB4740 | W | 20041110 | | |

AB A dry powder composition comprises recombinant human alpha 1-antitrypsin (rAAAT).

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:338322 CAPLUS
DN 134:357557
TI Dry powder compositions having improved dispersivity
IN Lechuga-Ballesteros, David; Kuo, Mei-Chang
PA Inhale Therapeutic Systems, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2001032144 | A1 | 20010510 | WO 2000-US9785 | 20000412 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2389219 | A1 | 20010510 | CA 2000-2389219 | 20000412 |
| | EP 1223915 | A1 | 20020724 | EP 2000-922117 | 20000412 |
| | EP 1223915 | B1 | 20051221 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | JP 2003513031 | T | 20030408 | JP 2001-534349 | 20000412 |
| | HU 2003001851 | A2 | 20030929 | HU 2003-1851 | 20000412 |
| | HU 2003001851 | A3 | 20060728 | | |
| | NZ 518401 | A | 20040130 | NZ 2000-518401 | 20000412 |
| | AU 775565 | B2 | 20040805 | AU 2000-42353 | 20000412 |
| | AT 313318 | T | 20060115 | AT 2000-922117 | 20000412 |
| | EP 1666028 | A1 | 20060607 | EP 2005-27610 | 20000412 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| | ES 2254164 | T3 | 20060616 | ES 2000-922117 | 20000412 |
| | US 6518239 | B1 | 20030211 | US 2000-548759 | 20000413 |
| | ZA 2002002855 | A | 20030821 | ZA 2002-2855 | 20020411 |
| | NO 2002001800 | A | 20020624 | NO 2002-1800 | 20020417 |
| | MX 2002PA04193 | A | 20021213 | MX 2002-PA4193 | 20020426 |
| | US 20030186894 | A1 | 20031002 | US 2002-313343 | 20021206 |
| | US 6835372 | B2 | 20041228 | | |

```
     US 20050147567       A1    20050707    US 2004-985509         20041110
PRAI US 1999-162451P      P     19991029
     US 1999-164236P      P     19991108
     US 1999-172769P      P     19991220
     US 2000-178383P      P     20000127
     US 2000-178415P      P     20000127
     EP 2000-922117       A3    20000412
     WO 2000-US9785       W     20000412
     US 2000-548759       A1    20000413
     US 2002-313343       A1    20021206
AB   The present invention provides a highly dispersible formulation comprising
     an active agent and a dipeptide or tripeptide comprising at least two
     leucyl residues.  The composition of the invention possesses superior aerosol
     properties and is thus preferred for aerosolized administration to the
     lung.  Also provided are a method for (i) increasing the dispersibility of
     an active-agent containing formulation for administration to the lung, and
     (ii) delivery of the composition to the lungs of a subject.  The surface
     tension of several representative di- and tripeptides and proteins was
     determined and highly surface active peptides include dileucine and trileucine.
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2   ANSWER 4 OF 6  BIOSIS  COPYRIGHT (c) 2008 The Thomson Corporation  on STN
AN   2000:290609  BIOSIS
DN   PREV200000290609
TI   Method and apparatus for pulmonary administration of dry powder
     alpha1-antitrypsin.
AU   Eljamal, Mohammed [Inventor, Reprint author]; Patton, John S. [Inventor]
CS   Santa Clara, CA, USA
     ASSIGNEE: Inhale Therapeutic Systems, Foster City, CA, USA
PI   US 5993783 19991130
SO   Official Gazette of the United States Patent and Trademark Office Patents,
     (Nov. 30, 1999) Vol. 1228, No. 5. e-file.
     CODEN: OGUPE7. ISSN: 0098-1133.
DT   Patent
LA   English
ED   Entered STN: 6 Jul 2000
     Last Updated on STN: 7 Jan 2002
AB   Dry powders of alpha1-antitrypsin are administered pulmonarily to patients
     to treat, for example, certain types of emphysema.  The dry powder
     compositions may comprise aggregates of fine particles, which aggregates
     are friable and break-up upon dispersion in a flowing gas stream.
     Typically, the dispersed powders are captured in a chamber and
     subsequently inhaled by a patient for pulmonary treatment of emphysema and
     other conditions.

L2   ANSWER 5 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   1998:478945  CAPLUS
DN   129:100052
TI   Method and apparatus for pulmonary administration of dry powder
     .alpha.1-antitrypsin
IN   Eljamal, Mohammed; Patton, John S.
PA   Inhale Therapeutic Systems, USA
SO   U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 423,515, abandoned.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 20
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 5780014           A     19980714    US 1996-617512         19960313
```

| | | | | | |
|---|---|---|---|---|---|
| | EP 940154 | A2 | 19990908 | EP 1999-110369 | 19920702 |
| | EP 940154 | B1 | 20070418 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE | | | | |
| | EP 1693080 | A2 | 20060823 | EP 2006-9725 | 19920702 |
| | EP 1693080 | A3 | 20070725 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC | | | | |
| | AT 359842 | T | 20070515 | AT 1999-110369 | 19920702 |
| | ES 2284226 | T3 | 20071101 | ES 1999-110369 | 19920702 |
| | US 6582728 | B1 | 20030624 | US 1995-423515 | 19950414 |
| | CA 2218208 | A1 | 19961017 | CA 1996-2218208 | 19960411 |
| | AU 9654825 | A | 19961030 | AU 1996-54825 | 19960411 |
| | AU 703491 | B2 | 19990325 | | |
| | EP 866726 | A1 | 19980930 | EP 1996-911736 | 19960411 |
| | EP 866726 | B1 | 20040303 | | |
| | EP 866726 | B2 | 20080109 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | AT 260688 | T | 20040315 | AT 1996-911736 | 19960411 |
| | ES 2217309 | T3 | 20041101 | ES 1996-911736 | 19960411 |
| | US 5993783 | A | 19991130 | US 1998-114713 | 19980713 |
| PRAI | US 1995-423515 | B2 | 19950414 | | |
| | US 1991-724915 | A | 19910702 | | |
| | EP 1992-914592 | A3 | 19920702 | | |
| | EP 1999-110369 | A3 | 19920702 | | |
| | US 1992-910048 | A2 | 19920708 | | |
| | US 1996-617512 | A | 19960313 | | |
| | WO 1996-US5062 | W | 19960411 | | |

AB Methods are provided for administering .alpha.1-antitrypsin dry powder pulmonarily to a patient. In these methods, .alpha.1-antitrypsin is provided in a dry powder form which is aerosolized and administered to the patient. Apparatus are also provided for carrying out these methods. These methods and apparatus are may generally be used in the treatment of patients suffering from α1-antitrypsin deficiency and the functional derangements of emphysema.

RE.CNT 128 THERE ARE 128 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1986:223816 CAPLUS
DN 104:223816
OREF 104:35489a,35492a
TI Preparation of fat and protein from banked human milk: its use in feeding very-low-birth-weight infants
AU Hylmoe, P.; Polberger, S.; Axelsson, I.; Jakobsson, I.; Raeihae, N.
CS Nordreco AB, Bjuv, Swed.
SO Nestle Nutrition Workshop Series (1984), 5(Hum. Milk Banking), 55-61
CODEN: NNWSDT; ISSN: 0742-2806
DT Journal
LA English
AB Pooled human milk samples were heated to .apprx.50°, the cream was separated, and frozen and the skim milk (<0.5% fat) was subjected to ultrafiltration to remove lactose, water-soluble salts, and some low-mol.-weight proteins and to concentrate the protein fraction. The protein concentrate was freeze-dried and stored at -20°. When used to supplement mothers milk or bank milk (final protein concentration .apprx.2 g/100 mL and final fat concentration .apprx.5.5 g/100 mL) a slight increase in osmolality and Ca content was observed The recovery of α-lactalbumin, lactoferrin, lysozyme [9001-63-2], and albumin in human milk protein supplement ranged from 60

to 100% of that found in natural milk. The recovery of lactoferrin and IgA in the human milk protein concentrate was substantial and the powder addnl. contained .alpha.1-antitrypsin [9041-92-3], amylase [9000-92-4], and lipase [9001-62-1]. The use of the supplement in feeding very-low-birth-weight infants is discussed.